快速降低抑郁症的3个支柱到5HT3-受体通过ECT或精神素?
1BipoSuisse - Psychiatrische Praxis, Vereinsweg 11, CH 3012 Berne, Switzerland, biposuisse@bluewin.ch.
Psychiatria Danubina
|October 8, 2024
概括
电疗法和迷幻药可以通过向5HT3血清道来快速缓解抑郁症. 这条通道对神经营养效应和突触功能至关重要,它会影响涉及抑郁症的线粒体和神经通路.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 精神病学是一个精神病学.
背景情况:
- 传统的抗抑郁药模型专注于血清素受体,但忽略了5HT3通道.
- 5HT3通道在抗抑郁药的神经营养转化和突触效应中起着至关重要的作用.
- 抑郁症的特点有三个主要支柱:线粒体功能障碍",推回"机制,以及与存在冲突相关的"羞耻链接".
研究的目的:
- 调查5HT3血清道在电疗法和迷幻药的快速抗抑郁作用中的作用.
- 探索5HT3通道在抑郁症的"三大支柱"中的参与:线粒体",pushback"和"羞耻链接".
- 为了阐明精神类药物,如 псилоцибин,可能通过5HT3相关途径发挥其抗抑郁作用的机制.
主要方法:
- 对有关血清素受体,5HT3通道和抗抑郁机制的现有文献的分析.
- 假设在与抑郁症相关的身体危机和神经效应中涉及寄附性"鼻腔"甲板 (PPG).
- 探索5HT3类通道在C. elegans等生物体中的潜在作用及其与迷幻作用的相关性.
主要成果:
- 5HT3通道对于所有抗抑郁药的神经营养转化和突触效应至关重要.
- 线粒体功能障碍,涉及到抑郁症的体质危机,受5HT3通道的影响.
- 骨 - 骨结节 (PPG) 涉及"推回"机制 (脑内内毒) 和"羞耻链接"现象 (导致羞耻的存在冲突).
- 像 псилоцибин这样的迷幻药物可能会利用类似5HT3的道来调节行为,这可能与它们在C. elegans等生物中的功能相似.
结论:
- 5HT3血清道是快速抗抑郁作用的关键目标,提供了超越传统模型的新视角.
- 了解5HT3通道在线粒体功能,PPG活动和神经交叉通话中的作用对于新型抑郁症治疗至关重要.
- 迷幻药的抗抑郁作用可能通过与5HT3相关的途径进行调解,突出其潜在的治疗应用.
关键词:
抑郁症相关概念视频
G-protein Coupled Receptors
116.8K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
116.8K
CNS Stimulants: Psychedelic Agents
127
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
127
Antidepressant Drugs: MAOIs and Other Agents
197
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
197
Depressive Disorders: Etiology
53
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
53
Antidepressant Drugs: Overview
372
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
372
Electroconvulsive Therapy
26
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
26


